Tag:

Daiichi Sankyo

Latest Headlines

Latest Headlines

Daiichi clot-buster wins a NICE green light, but still faces an uphill track

As the fourth market entrant in a hotly contested group of new-age anticoagulants, Daiichi Sankyo's Lixiana (edoxaban) has some ground to make up. Luckily, it got a boost in the U.K. that could help it build momentum.

India's Sun sees sharp Q1 profit drop, but Shanghvi not worried

India's top drugmaker and fifth largest in generics globally saw net profit plunge 60% in the first quarter of its financial year as it absorbed costs from its takeover of Ranbaxy Laboratories earlier in 2015, but founder and managing director Dilip Shanghvi pledged that integration would eventually bring greater rewards.

Daiichi Sankyo puts $80M into Tokyo vaccine plant

Daiichi Sankyo has some new vaccines in the pipeline and is getting prepared for their production with the soon-to-be-completed expansion of a plant in Tokyo.

Actelion's Tracleer recommended for additional indication by Japan's PAFSC

Actelion's Tracleer was recommended by Japan's Pharmaceutical Affairs and Food Sanitation Council (PAFSC) for an additional indication aimed at reducing ulcers in patients with generalized scleroderma, a spokesman for the Ministry of Health Labor and Welfare said.

India's Zenotech committee says Sun Pharma stake offer 'fair and reasonable'

An INR202.3 million ($3.2 million) offer for a 28% stake in India's Zenotech Laboratories by Sun Pharmaceutical Industries is "fair and reasonable," according to a special committee named by the target company to evaluate the proposed transaction.

AZ, Daiichi sign up Olympian Joyner-Kersee, hoping OIC patients will make tracks to Movantik

When you're targeting an under-the-radar malady that hasn't traditionally been treated with prescription drugs, it's up to marketers to get the word out and deliver on sales. And that's why AstraZeneca and Daiichi Sankyo, whose Movantik launched earlier this year, are bringing a 6-time Olympic medalist on board to talk about opioid-induced constipation (OIC).

Japan's Daiichi Sankyo still on the hook for Ranbaxy bills?

Think Daiichi Sankyo set itself free of Ranbaxy Laboratories when it sold its stock in Sun Pharmaceuticals Industries? Think again. It remains possibly liable until 2022 for another $325 million as the Ranbaxy mess is cleaned up in the United States.

Founder Dilip Shanghvi did not buy Daiichi stake, Sun Pharmaceutical says

It would appear that Sun Pharmaceuticals founder, Managing Director and CEO Dilip Shanghvi was not the buyer of Daiichi Sankyo's one-swoop sale of its 8.9% stake in the company it received for selling Ranbaxy Laboratories.

Daiichi Sankyo turned over Ranbaxy's problems to Sun, now cashing in its stake

In a regulatory filing, Japan's Daiichi Sankyo said that its board has agreed to it selling some or all of its shares in Sun Pharmaceutical, which Reuters reports are now worth about $3.6 billion. No reason was given, the news service said, but its experience with Ranbaxy, which was recently acquired by Sun, has been nonstop issues.

Daiichi Sankyo cashing out after merging Ranbaxy with Sun

Daiichi Sankyo has had enough of trying to make money in the Indian generic drug industry. The Japanese drugmaker, which faces patent cliff issues, is selling off its stake in Sun Pharmaceutical just weeks after it closed on the all-stock deal selling Ranbaxy Laboratories to Sun for $3.2 billion.